Is DexCom Inc (DXCM) overvalued? · P/E 63, rev $2.50B
DexCom Inc (DXCM) is a medical devices company listed on US.
This page asks whether DexCom Inc (DXCM) looks expensive on cached numbers — not a short thesis.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DXCM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DXCM stock page for the full model, not this heading.
Not investment advice.